@article{7384e79e85024edba05861076d935e16,
title = "Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors",
author = "Barliz Waissengrin and Abed Agbarya and Esraa Safadi and Hagit Padova and Ido Wolf",
note = "Funding Information: IW and BW contributed to conception and design of the study. BW, AA, ES, and HP contributed to collection and analysis of data. BW and IW contributed to data analysis and interpretation. All authors contributed to writing of the Comment and approved the final version before submission. This study had no funding. BW reports speaker fees and fees for consultancy from MSD. AA reports speaker fees and fees for consultancy from MSD, Roche, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Pfizer, Bristol Meyers Squibb, Novartis, Merck Serono, Sanofi, Oncotest-Teva, Medison, AbbVie, and Takeda; grants from Altman Health; and is a member of the board for the Israeli Lung Cancer Advocacy Group. IW reports speaker fees and fees for consultancy from Roche, Bristol Myers Squibb, MSD, and Novartis, and research funding from Roche and MSD. ES and HP declare no competing interests. No individual participant-level data will be shared. ",
year = "2021",
month = may,
doi = "10.1016/S1470-2045(21)00155-8",
language = "אנגלית",
volume = "22",
pages = "581--583",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "5",
}
